Q-Line Biotech Limited

<table><tr><td>(iv)</td><td>ISE Refilling Solution</td></tr><tr><td>(v)</td><td>Reference Electrode Filling Solution</td></tr><tr><td>(vi)</td><td>De-Protein Solution</td></tr><tr><td>(vii)</td><td>PVC Electrode Activating Solution</td></tr><tr><td>(viii)</td><td>Dengue Antibody (IgM/IgG)</td></tr><tr><td>(ix)</td><td>β – HCG (Beta-hCG)</td></tr><tr><td>(x)</td><td>Scrub Typus Antibody (IgM/IgG)</td></tr><tr><td>(xi)</td><td>Leptospira IgM/IgG</td></tr><tr><td>(xii)</td><td>FOB</td></tr><tr><td>(xiii)</td><td>Urine Strip</td></tr><tr><td>(xiv)</td><td>Ammonia (NH3)</td></tr><tr><td>(xv)</td><td>Glucose-6PDH</td></tr><tr><td>(xvi)</td><td>Lipase</td></tr><tr><td>(xvii)</td><td>ACE</td></tr><tr><td>(xviii)</td><td>Vitamin D</td></tr><tr><td>(xix)</td><td>Diluent</td></tr><tr><td>(xx)</td><td>Lyse</td></tr><tr><td>(xxi)</td><td>Hb Strips</td></tr><tr><td>(xxii)</td><td>Lipid Strips</td></tr><tr><td>(xxiii)</td><td>Glucose Strips</td></tr></table>

d. The Company has filed an application (Form MD-7) dated September 06, 2025 bearing transaction id 0609250029878 for Grant of Licence to Manufacture for Sale or for Distribution of Class C or Class D medical device which are as under:

<table><tr><td>(i)</td><td>HIV 1 & 2 RT-PCR</td></tr><tr><td>(ii)</td><td>HBV RT-PCR</td></tr><tr><td>(iii)</td><td>HCV RT-PCR</td></tr><tr><td>(iv)</td><td>HBV/HCV/HIV RT-PCR</td></tr><tr><td>(v)</td><td>Dengue RT-PCR</td></tr><tr><td>(vi)</td><td>MTB RT-PCR</td></tr><tr><td>(vii)</td><td>Covid-19 RT PCR Orflab & N Gene</td></tr><tr><td>(viii)</td><td>nCov-19 RT PCR E & RdRP Gene</td></tr></table>

e. The Company has filed an application (Form MD-7) dated September 11, 2025 bearing transaction id 1109250041029 for Grant of Licence to Manufacture for Sale or for Distribution of Class C or Class D medical device which are as under:

<table><tr><td>(i)</td><td>HIV 1 & 2 Antibody 3rd Gen ELISA</td></tr><tr><td>(ii)</td><td>HIV Ag-Ab 4th Gen ELISA</td></tr><tr><td>(iii)</td><td>HBsAg ELISA</td></tr><tr><td>(iv)</td><td>HBsAg High Sensitive ELISA</td></tr><tr><td>(v)</td><td>HCV Antibody ELISA</td></tr><tr><td>(vi)</td><td>Syphilis Antibody ELISA</td></tr><tr><td>(vii)</td><td>Dengue NS1 Antigen ELISA</td></tr><tr><td>(viii)</td><td>COVID-19 IgG Antibody ELISA</td></tr></table>

f. The Company has filed an application (Form MD-7) dated September 23, 2025 bearing transaction id 2309250045160 for Grant of Licence to Manufacture for Sale or for Distribution of Class C or Class D medical device which are as under:

<table><tr><td>(i)</td><td>FIA Cardiac Troponin I</td></tr><tr><td>(ii)</td><td>FIA NT- proBNP</td></tr><tr><td>(iii)</td><td>FIA hs-CRP+CRP</td></tr><tr><td>(iv)</td><td>FIA Procalcitonin (PCT)</td></tr><tr><td>(v)</td><td>FIA CK-MB/cTnI/Myo</td></tr><tr><td>(vi)</td><td>Q-Line® FIA beta-2-MG</td></tr><tr><td>(vii)</td><td>FIA D-Dimer</td></tr></table>

g. The Company has filed an application (Form MD-7) dated September 29, 2025 bearing transaction id 2909250047993 for Grant of Licence to Manufacture for Sale or for Distribution of Class C or Class D medical device which are as under:

<table><tr><td>(i)</td><td>HIV 1&2 Antibody;</td></tr><tr><td>(ii)</td><td>HIV Ag-Ab 4th Generation;</td></tr></table>

306